Literature DB >> 15849491

Somatostatin-producing pancreatic endocrine carcinoma presented as relapsing cholangitis -- a case report.

George Marakis1, Konstantinos Ballas, Savas Rafailidis, Michael Alatsakis, Kalliopi Patsiaoura, Athanassios Sakadamis.   

Abstract

Somatostatin-producing endocrine tumors are rare neoplasms usually arising in the pancreas and duodenum and they account for less than 1% of all gastrointestinal endocrine tumors. Besides somatostatinoma syndrome, which is characterized by diabetes mellitus, steatorrhea and cholelithiasis, patients with somatostatin-producing endocrine tumors commonly complain of nonspecific symptoms such as vague abdominal pain, weight loss or changes in bowel habits. Tumor behavior cannot be predicted by histological features alone, and malignancy is determined by the presence of metastases. We report here a case of malignant pancreatic endocrine tumor producing somatostatin presented as relapsing cholangitis who was treated with Whipple pancreatoduodenectomy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15849491     DOI: 10.1159/000085286

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  3 in total

1.  Two synchronous somatostatinomas of the duodenum and pancreatic head in one patient.

Authors:  Radoje B Colović; Slavko V Matić; Marjan T Micev; Nikica M Grubor; Henry Dushan Atkinson; Stojan M Latincić
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

2.  Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern.

Authors:  Bo Zhang; Qiu-ping Xie; Shun-liang Gao; Yan-biao Fu; Yu-lian Wu
Journal:  J Zhejiang Univ Sci B       Date:  2010-01       Impact factor: 3.066

3.  Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Eleni Papoutsi; Vasiliki Ntella; Prodromos Kanavidis; Athanasios Sioulas; Marina Tsoli; Georgios Charalampopoulos; Michail Vailas; Evangelos Felekouras
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.